ADP-A2M4CD8 in HLA-A2+ Subjects With MAGE-A4 Positive Esophageal or Esophagogastric Junction Cancers (SURPASS-2)

PHASE2TerminatedINTERVENTIONAL
Enrollment

3

Participants

Timeline

Start Date

September 15, 2021

Primary Completion Date

June 9, 2023

Study Completion Date

December 15, 2023

Conditions
Esophageal CancerEsophagogastric Junction Cancer
Interventions
GENETIC

Autologous genetically modified ADP-A2M4CD8 cells

Infusion of autologous genetically modified ADP-A2M4CD8 on Day 1

Trial Locations (17)

10065

Memorial Sloan Kettering Cancer Center, New York

28041

Hospital Universitario 12 de Octubre, Córdoba

28050

Hospital Universitario Madrid Sanchinarro (CIOCC), Madrid

31008

Clinica Universidad de Navarra, Navarro

41013

Hospital Universitario Virgen del Rocio, Seville

46010

Hospital Clinico Universitario de Valencia, Ibáñez

53792

University Of Wisconsin Clinical Science Center, Madison

60637

University of Chicago Medicine, Chicago

63110

Washington University School of Medicine- Siteman Cancer Center, St Louis

73104

OU Health Stephenson Cancer Center, Oklahoma City

77030

University Of Texas, MD Anderson Cancer Center, Houston

91010

City of Hope National Medical Center, Duarte

97213

Providence Cancer Institute Franz Clinic, Portland

228040

Hospital Fundacion Jimenez Diaz, Madrid

M5G 2M9

Princess Margaret Cancer Centre, Toronto

H4A 3J1

McGill University Health Centre Glen Site, Montreal

08035

Hospital Universitari Vall d'Hebron, la Vall d'Hebron

Sponsors

Lead Sponsor

Collaborators (1)

All Listed Sponsors
collaborator

ICON plc

INDUSTRY

lead

Adaptimmune

INDUSTRY